Safety and Immunogenicity of a 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Chinese Children, Adults and the Elderly: A Phase 4, Randomized, Double-Blind, Active-Controlled Clinical Trial
The PPSV23 vaccine administered among individual aged ≥2 years was safe, well tolerated and immunogenic, eliciting an immune response either comparable to or higher than control vaccine. These findings support its use as a safe and effective option for pneumococcal immunization.
Authors
- Xiaohua Ye (ORCID: https://orcid.org/0009-0002-8590-9880)
- Yuehong Ma (ORCID: https://orcid.org/0000-0002-7700-7628)
- Juxiang Zhang (ORCID: https://orcid.org/0000-0002-0886-8678)
- Wanqi Yang
- Dan Song (ORCID: https://orcid.org/0000-0002-2417-9899)
- Weijun Hu (ORCID: https://orcid.org/0000-0002-3039-6523)
- Hong Li (ORCID: https://orcid.org/0000-0002-6795-5560)
- Yinan Wang (ORCID: https://orcid.org/0000-0002-4079-1658)
- Xiaoyu Liu (ORCID: https://orcid.org/0000-0001-9888-5836)
- Gang Shi (ORCID: https://orcid.org/0000-0002-8193-183X)
- Xinyi Yang (ORCID: https://orcid.org/0000-0002-0171-5003)
- Dan Yu (ORCID: https://orcid.org/0000-0002-1720-3432)
- Yuanyuan Dong (ORCID: https://orcid.org/0000-0003-3796-0817)
- Zeng Wang
Institutions
- Sinovac Biotech (CN)
- Xian Center for Disease Control and Prevention (CN)
- National Institutes for Food and Drug Control (CN)
- Taiwan Centers for Disease Control (TW)
Publication Details
- Journal
- Vaccines
- Published
- 2025-08-15
- DOI
- https://doi.org/10.3390/vaccines13080866
- Citations
- 2
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 2.71